Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics

被引:49
作者
Becquemont, L. [1 ]
Neuvonen, M.
Verstuyft, C.
Jaillon, P.
Letierce, A.
Neuvonen, P. J.
Funck-Brentano, C.
机构
[1] Hop Bicetre, AP HP, Serv Genet Mol & Pharmacogenet, Le Kremlin Bicetre, France
[2] Univ Paris 11, Dept Pharmacol, Unite Rech Clin, Le Kremlin Bicetre, France
[3] Univ Paris 11, Dept Pharmacol, Ctr Invest Biol, Le Kremlin Bicetre, France
[4] Univ Paris Sud, Dept Pharmacol, Fac Med, Le Kremlin Bicetre, France
[5] Univ Helsinki, Dept Clin Pharmacol, FIN-00014 Helsinki, Finland
[6] Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland
[7] Hop St Antoine, Serv Pharmacol, F-75571 Paris, France
[8] Univ Paris 06, Fac Med, Dept Pharmacol, Paris, France
[9] Univ Paris 06, Dept Pharmacol, Ctr Invest Clin, Paris, France
[10] INSERM, Paris, France
关键词
D O I
10.1038/sj.clpt.6100098
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to determine the influence of amiodarone on the pharmacokinetics of simvastatin and pravastatin in humans. This was a prospective, crossover, randomized, open-label study performed in 12 healthy volunteers comparing the pharmacokinetics of a single oral dose of simvastatin ( 40 mg) or pravastatin ( 40 mg) taken alone and after 3 days of amiodarone ( 400 mg/day). Amiodarone increased simvastatin acid AUC ( area under the plasma concentration-time curve)(0-24h), peak plasma concentration ( C-max), and t(1/2) by 73% ( P = 0.02), 100% ( P = 0.02), and 48% ( P = 0.06), respectively, whereas it did not significantly alter pravastatin pharmacokinetics. Point estimates and 90% confidence intervals for simvastatin acid, simvastatin lactone, and pravastatin AUC(0-24) h were 154% ( 109-216%), 155% ( 109-227%), and 86% ( 63-118%), respectively. If amiodarone and a statin have to be simultaneously prescribed, pravastatin should be preferred to simvastatin in order to avoid a drug interaction.
引用
收藏
页码:679 / 684
页数:6
相关论文
共 34 条
  • [1] [Anonymous], DRUG INT STUD STUD D
  • [2] The interaction of diltiazem with lovastatin and pravastatin
    Azie, NE
    Brater, DC
    Becker, PA
    Jones, DR
    Hall, SD
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (04) : 369 - 377
  • [3] Plasma concentrations of active simvastatin acid are increased by gemfibrozil
    Backman, JT
    Kyrklund, C
    Kivistö, KT
    Wang, JS
    Neuvonen, PJ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (02) : 122 - 129
  • [4] Drug interactions with lipid lowering drugs
    Becquemont, L
    [J]. THERAPIE, 2003, 58 (01): : 85 - 90
  • [5] Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics
    Becquemont, L
    Funck-Brentano, C
    Jaillon, P
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1999, 13 (02) : 232 - 236
  • [6] Statin safety and drug interactions: Clinical implications
    Bottorff, MB
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (8A) : 27C - 31C
  • [7] Differential interaction of 3-hydroxy-3-methylglutaryl-COA reductase inhibitors with ABCB1, ABCC2, and OATP1B1
    Chen, CP
    Mireles, RJ
    Campbell, SD
    Lin, J
    Mills, JB
    Xu, JHJ
    Smolarek, TA
    [J]. DRUG METABOLISM AND DISPOSITION, 2005, 33 (04) : 537 - 546
  • [8] Simvastatin interaction with clarithromycin and amiodarone causing myositis
    Chouhan, UM
    Chakrabarti, S
    Millward, LJ
    [J]. ANNALS OF PHARMACOTHERAPY, 2005, 39 (10) : 1760 - 1761
  • [9] CONNOLLY S, 1988, AM HEART J, V115
  • [10] RELATIONSHIP OF STEADY-STATE SERUM CONCENTRATIONS OF AMIODARONE AND DESETHYLAMIODARONE TO THERAPEUTIC EFFICACY AND ADVERSE-EFFECTS
    FALIK, R
    FLORES, BT
    SHAW, L
    GIBSON, GA
    JOSEPHSON, ME
    MARCHLINSKI, FE
    [J]. AMERICAN JOURNAL OF MEDICINE, 1987, 82 (06) : 1102 - 1108